-
1
-
-
33748445698
-
Malignancy and hemostasis
-
5th edition (Eds. R.W. Colman, J. Hirsh, V.J. Marder, A.W. Clowes and J.N. George). Lippincott- Raven Publishers, Philadelphia, PA, Chapter 57
-
Dvorak HF, Rickles FR. Malignancy and hemostasis. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 5th edition (Eds. R.W. Colman, J. Hirsh, V.J. Marder, A.W. Clowes and J.N. George). Lippincott- Raven Publishers, Philadelphia, PA, 2006; Chapter 57, pp. 851-73.
-
(2006)
Hemostasis and Thrombosis: Basic Principles and Clinical Practice
, pp. 851-873
-
-
Dvorak, H.F.1
Rickles, F.R.2
-
3
-
-
49849097799
-
Tissue factor-bearing microparticles derived from tumor cells: Impact on blood coagulation
-
Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, et al. Tissue factor-bearing microparticles derived from tumor cells: Impact on blood coagulation. J Thromb Haemost 2008;6:1517 24.
-
(2008)
J Thromb Haemost
, vol.6
, pp. 1517-1524
-
-
Davila, M.1
Amirkhosravi, A.2
Coll, E.3
Desai, H.4
Robles, L.5
Colon, J.6
-
4
-
-
48749103173
-
Tissue factor-bearing microparticles and cancer
-
Zwicker J. Tissue factor-bearing microparticles and cancer. Sem Thromb Haem 2008; 34:195-8.
-
(2008)
Sem Thromb Haem
, vol.34
, pp. 195-198
-
-
Zwicker, J.1
-
5
-
-
33846941576
-
Tissue factor-positive microparticles: Cellular origin and association with coagulation activation in patients with colorectal cancer
-
Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, Eichinger S, et al. Tissue factor-positive microparticles: Cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007; 97:119 23.
-
(2007)
Thromb Haemost
, vol.97
, pp. 119-123
-
-
Hron, G.1
Kollars, M.2
Weber, H.3
Sagaster, V.4
Quehenberger, P.5
Eichinger, S.6
-
6
-
-
34247606502
-
Microparticle-associated tissue factor activity: A link between cancer and thrombosis?
-
Tesselaar MET, Romijn FPHTM, Van der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: A link between cancer and thrombosis? J Thromb Haemost 2007;5:520-7.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 520-527
-
-
Tesselaar, M.E.T.1
Fphtm, R.2
Van Der Linden, I.K.3
Prins, F.A.4
Bertina, R.M.5
Osanto, S.6
-
7
-
-
33845549003
-
Microvesicle-associated tissue factor and Trousseau's syndrome
-
Del Conde I, Bharwani LD, Dietzen DJ, Pendurthi U, Thiagarajan P, Lopez JA. Microvesicle-associated tissue factor and Trousseau's syndrome. J Thromb Haemost 2007;5:70-4.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 70-74
-
-
Del Conde, I.1
Bharwani, L.D.2
Dietzen, D.J.3
Pendurthi, U.4
Thiagarajan, P.5
Lopez, J.A.6
-
8
-
-
34249806307
-
Tissue factor expression, angiogenesis and thrombosis in pancreatic cancer
-
Khorana A, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, et al. Tissue factor expression, angiogenesis and thrombosis in pancreatic cancer. Clin Cancer Res 2007; 13:2870-5.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 2870-2875
-
-
Khorana, A.1
Ahrendt, S.A.2
Ryan, C.K.3
Francis, C.W.4
Hruban, R.H.5
Hu, Y.C.6
-
9
-
-
15244345941
-
The MET oncogene drives a genetic programme linking cancer to haemostasis
-
Boccaccio C, Sabatino G, Medico E, Girolami F, Follenzi A, Reato G, et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005; 434:396 400.
-
(2005)
Nature
, vol.434
, pp. 396-400
-
-
Boccaccio, C.1
Sabatino, G.2
Medico, E.3
Girolami, F.4
Follenzi, A.5
Reato, G.6
-
10
-
-
13944256192
-
PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma
-
Rong Y, Post DE, Pieper RO, Burden DL, Van Meir EG, Brat DJ. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005; 65:1406 13.
-
(2005)
Cancer Res
, vol.65
, pp. 1406-1413
-
-
Rong, Y.1
Post, D.E.2
Pieper, R.O.3
Burden, D.L.4
Van Meir, E.G.5
Brat, D.J.6
-
11
-
-
13544256266
-
Oncogenic events regulate tissue factor expression in colorectal cancer cells: Implications for tumor progression and angiogenesis
-
Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: Implications for tumor progression and angiogenesis. Blood 2005;105: 1734 41.
-
(2005)
Blood
, vol.105
, pp. 1734-1741
-
-
Yu, J.L.1
May, L.2
Lhotak, V.3
Shahrzad, S.4
Shirasawa, S.5
Weitz, J.I.6
-
12
-
-
13044277569
-
Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor
-
Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999;96:8663-8.
-
(1999)
Proc Natl Acad Sci USA
, vol.96
, pp. 8663-8668
-
-
Abe, K.1
Shoji, M.2
Chen, J.3
Bierhaus, A.4
Danave, I.5
Micko, C.6
-
13
-
-
2442700125
-
Regulation of angiogenesis by tissue factor cytoplasmic domain signaling
-
Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A, et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004;10: 502-9.
-
(2004)
Nat Med
, vol.10
, pp. 502-509
-
-
Belting, M.1
Dorrell, M.I.2
Sandgren, S.3
Aguilar, E.4
Ahamed, J.5
Dorfleutner, A.6
-
14
-
-
7244231210
-
Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis
-
Hu L, Lee M, Campbell W, Perez-Soler R, Karpatkin S. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 2004;104:2746 51.
-
(2004)
Blood
, vol.104
, pp. 2746-2751
-
-
Hu, L.1
Lee, M.2
Campbell, W.3
Perez-Soler, R.4
Karpatkin, S.5
-
15
-
-
0032841392
-
Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: Risk analysis using Medicare claims data
-
Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: Risk analysis using Medicare claims data. Medicine 1999;78:285-91.
-
(1999)
Medicine
, vol.78
, pp. 285-291
-
-
Levitan, N.1
Dowlati, A.2
Remick, S.C.3
Tahsildar, H.I.4
Sivinski, L.D.5
Beyth, R.6
-
17
-
-
0034164514
-
Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic surgery: A prospective randomized, double-blind trial
-
von Templehoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic surgery: A prospective randomized, double-blind trial. Int J Oncol 2000;16:815 24.
-
(2000)
Int J Oncol
, vol.16
, pp. 815-824
-
-
Von Templehoff, G.F.1
Harenberg, J.2
Niemann, F.3
Hommel, G.4
Kirkpatrick, C.J.5
Heilmann, L.6
-
18
-
-
3042704507
-
Low molecular weight heparin, therapy with Dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS)
-
Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, et al. Low molecular weight heparin, therapy with Dalteparin, and survival in advanced cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004;21:1944-8.
-
(2004)
J Clin Oncol
, vol.21
, pp. 1944-1948
-
-
Kakkar, A.K.1
Levine, M.N.2
Kadziola, Z.3
Lemoine, N.R.4
Low, V.5
Patel, H.K.6
-
19
-
-
12844289104
-
A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer
-
Altinbass M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1266 71.
-
(2004)
J Thromb Haemost
, vol.2
, pp. 1266-1271
-
-
Altinbass, M.1
Coskun, H.S.2
Er, O.3
Ozkan, M.4
Eser, B.5
Unal, A.6
-
20
-
-
17144385138
-
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism
-
LeeAYY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-9.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2123-2129
-
-
Lee, A.Y.Y.1
Rickles, F.R.2
Julian, J.A.3
Gent, M.4
Baker, R.I.5
Bowden, C.6
-
21
-
-
20244376337
-
The effect of low molecular weight heparin on survival in patients with advanced malignancy
-
Klerk CPW, Smorenburg SM, Otten H-M, Lensing AWA, Prins MH, Piovella F, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-5.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2130-2135
-
-
Klerk, C.P.W.1
Smorenburg, S.M.2
Otten, H.-M.3
Lensing, A.W.A.4
Prins, M.H.5
Piovella, F.6
-
22
-
-
0020572581
-
Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone
-
Folkman J, Langer R, Linhardt RJ, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983;221:719 25.
-
(1983)
Science
, vol.221
, pp. 719-725
-
-
Folkman, J.1
Langer, R.2
Linhardt, R.J.3
Haudenschild, C.4
Taylor, S.5
-
23
-
-
0032699382
-
Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread
-
Hettiarachchi RJK, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999;82:947-52.
-
(1999)
Thromb Haemost
, vol.82
, pp. 947-952
-
-
Hettiarachchi, R.J.K.1
Smorenburg, S.M.2
Ginsberg, J.3
Levine, M.4
Prins, M.H.5
Buller, H.R.6
-
24
-
-
0034326271
-
Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro
-
Collen A, Smorenburg SM, Peters E, Lupu F, Koolwijk P, Van Noorden C, et al. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Research 2001;60:6196 200.
-
(2001)
Cancer Research
, vol.60
, pp. 6196-6200
-
-
Collen, A.1
Smorenburg, S.M.2
Peters, E.3
Lupu, F.4
Koolwijk, P.5
Van Noorden, C.6
-
25
-
-
1842463681
-
Antimetastatic effect of tinzaparin, a low-molecularweight heparin
-
Amirkhosravi A, Mousa SA, Amaya M, Francis JL. Antimetastatic effect of tinzaparin, a low-molecularweight heparin. J Thromb Haemost 2003;1:1972-6.
-
(2003)
J Thromb Haemost
, vol.1
, pp. 1972-1976
-
-
Amirkhosravi, A.1
Mousa, S.A.2
Amaya, M.3
Francis, J.L.4
-
26
-
-
0141671526
-
Unfractionated heparin (UFH) and a low molecular weight heparin (dalteparin) exhibit antiangiogenic effects using in vitro, ex vivo and in vivo angiogenesis models
-
Fernandez PM, Chou DS, Aquilina JW, Patierno SR, Rickles FR. Unfractionated heparin (UFH) and a low molecular weight heparin (dalteparin) exhibit antiangiogenic effects using in vitro, ex vivo and in vivo angiogenesis models. Proc Am Assoc Cancer Res 2003;44:698-9.
-
(2003)
Proc Am Assoc Cancer Res
, vol.44
, pp. 698-699
-
-
Fernandez, P.M.1
Chou, D.S.2
Aquilina, J.W.3
Patierno, S.R.4
Rickles, F.R.5
-
27
-
-
28144447451
-
Heparin octasaccharides inhibit angiogenesis in vivo
-
Hasan J, Shnyder SD, Clamp AR, McGown AT, Bicknell R, Presta M, et al. Heparin octasaccharides inhibit angiogenesis in vivo. Clin Cancer Res 2005;11:8172-9.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 8172-8179
-
-
Hasan, J.1
Shnyder, S.D.2
Clamp, A.R.3
McGown, A.T.4
Bicknell, R.5
Presta, M.6
-
28
-
-
0034904048
-
Molecular properties and involvement of heparase in cancer metastasis and angiogenesis
-
Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparase in cancer metastasis and angiogenesis. J Clin Invest 2001;108:341-7.
-
(2001)
J Clin Invest
, vol.108
, pp. 341-347
-
-
Vlodavsky, I.1
Friedmann, Y.2
-
29
-
-
26444566779
-
Differential metastasis inhibition by clinically relevant levels of heparins correlation with selectin inhibition, not antithrombotic activity
-
Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 2005;11:7003 11.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 7003-7011
-
-
Stevenson, J.L.1
Choi, S.H.2
Varki, A.3
-
30
-
-
0031026481
-
Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature
-
Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997;275:547 50.
-
(1997)
Science
, vol.275
, pp. 547-550
-
-
Huang, X.1
Molema, G.2
King, S.3
Watkins, L.4
Edgington, T.S.5
Thorpe, P.E.6
-
31
-
-
0033529314
-
Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model
-
Hu Z, Sun Y, Garen A. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Acad Sci USA 1999;96:8161-6.
-
(1999)
Proc Natl Acad Sci USA
, vol.96
, pp. 8161-8166
-
-
Hu, Z.1
Sun, Y.2
Garen, A.3
-
32
-
-
0035863566
-
Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice
-
Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001;61:711-6.
-
(2001)
Cancer Res
, vol.61
, pp. 711-716
-
-
Nilsson, F.1
Kosmehl, H.2
Zardi, L.3
Neri, D.4
-
33
-
-
28244486499
-
A selective tumor microvasculature thrombogen that targets a novel receptor complex in the tumor angiogenic microenvironment
-
El-Sheikh A, Borgstrom P, Bhattacharjee G, Belting M, Edgington TS. A selective tumor microvasculature thrombogen that targets a novel receptor complex in the tumor angiogenic microenvironment. Cancer Res 2005; 65:11109-17.
-
(2005)
Cancer Res
, vol.65
, pp. 11109-11117
-
-
El-Sheikh, A.1
Borgstrom, P.2
Bhattacharjee, G.3
Belting, M.4
Edgington, T.S.5
-
34
-
-
0035834011
-
Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer
-
Hu Z, Garen A. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl Acad Sci USA 2001;98:12180-5.
-
(2001)
Proc Natl Acad Sci USA
, vol.98
, pp. 12180-12185
-
-
Hu, Z.1
Garen, A.2
-
35
-
-
2942726181
-
Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and antiangiogenesis agents
-
Adams BK, Ferstl EM, Davis MC, Herold M, Kurtkaya S, Camalier RF, et al. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and antiangiogenesis agents. Bioorg Med Chem 2004;12: 83
-
(2004)
Bioorg Med Chem
, vol.12
, pp. 83
-
-
Adams, B.K.1
Ferstl, E.M.2
Davis, M.C.3
Herold, M.4
Kurtkaya, S.5
Camalier, R.F.6
-
37
-
-
25444456891
-
Afunctional role for hemostasis in early cancer development
-
Boccaccio C, Comoglio PM.Afunctional role for hemostasis in early cancer development. Cancer Res 2005;65: 8579-82.
-
(2005)
Cancer Res
, vol.65
, pp. 8579-8582
-
-
Boccaccio, C.1
Comoglio, P.M.2
-
39
-
-
84873653213
-
OT-304, a novel, anti-tumor agent with multiple inhibitory effects on tumor proliferation, angiogenesis and tumor progression
-
May 20 Suppl): Abstract # 14597
-
Mousa SA, Patil G, Tyhangirala S, Dier E, Dyskin E, Yalcin M, et al. OT-304, a novel, anti-tumor agent with multiple inhibitory effects on tumor proliferation, angiogenesis and tumor progression. J Clin Oncol 2008;26(May 20 Suppl): Abstract # 14597.
-
(2008)
J Clin Oncol
, vol.26
-
-
Mousa, S.A.1
Patil, G.2
Tyhangirala, S.3
Dier, E.4
Dyskin, E.5
Yalcin, M.6
-
40
-
-
84873658550
-
PCI-27483, a small molecule inhibitor of Factor VIIa, inhibits growth of BxPC3 pancreatic adenocarcinoma xenograft tumors
-
Abstract #5669
-
Loury DJ, Thiemann P, Prescott JE, Buggy J. PCI-27483, a small molecule inhibitor of Factor VIIa, inhibits growth of BxPC3 pancreatic adenocarcinoma xenograft tumors. Proc Meeting AACR, 2008; Abstract #5669.
-
(2008)
Proc Meeting AACR
-
-
Loury, D.J.1
Thiemann, P.2
Prescott, J.E.3
Buggy, J.4
-
41
-
-
0345701292
-
Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration
-
Bora PS, Hu Z, Tezel TH, Sohn J-H, Kang SG, Cruz JMC, et al. Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration. Proc Natl Acad Sci USA 2003;100: 2679-84.
-
(2003)
Proc Natl Acad Sci USA
, vol.100
, pp. 2679-2684
-
-
Bora, P.S.1
Hu, Z.2
Tezel, T.H.3
Sohn, J.-H.4
Kang, S.G.5
Cruz, J.M.C.6
-
42
-
-
34248334629
-
Protective effect of TEMPOL derivatives against lightinduced retinal damage in rats
-
Tanito M, Li F, Elliot MH, Dittmar M, Anderson TE. Protective effect of TEMPOL derivatives against lightinduced retinal damage in rats. Invest Ophth Vis Sci 2007;48:1900 5.
-
(2007)
Invest Ophth Vis Sci
, vol.48
, pp. 1900-1905
-
-
Tanito, M.1
Li, F.2
Elliot, M.H.3
Dittmar, M.4
Anderson, T.E.5
|